Chronic obstructive pulmonary disease and asthma: mesenchymal stem cells and their extracellular vesicles as potential therapeutic tools

HIGHLIGHTS

• who: Hossein Abbaszadeh from the be safe and made no remarkable change in frequency of COPD exacerbations, severity of disease and radiological outcomesNonetheless, the, reactive protein (CRP) levels was decreased in days , and , and quality of life was improved in the BMu2010MSC-treated group. Short following-up period, low number of participants, and evaluation of inflammatory mediators only in plasma was the major disadvantages of this study [58]. Similarly, treatment of COPD patients with BM-derived mononuclear cells (BM-MCs), heterogeneous pool of cells which contains MSCs, has displayed emerging outcomes. In, one phase I clinical trial . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.